Beijing Foyou Pharma (601089.SH): Benidipine Hydrochloride Tablets Obtained Drug Registration Certificate.
Fuyuan Pharmaceutical (601089.SH) announced that recently the company received a notice from the National Medical Products Administration (NMPA)...
Beijing Foyou Pharma (601089.SH) announced that it has recently received the Drug Registration Certificate (Certificate No. 2025S02068) for the production of Benidipine Hydrochloride tablets (4mg) from the National Medical Products Administration.
Related Articles
Minami Acoustics (301383.SZ) plans to establish a wholly-owned subsidiary in Ganzhou City.
AOM INT'L (00381) proposes to issue approximately 157.8 million subscription shares at a discount of approximately 11.15%.
Shareholder Zhangzhou Jin Wanchen of Fujian Wanchen Biotechnology Group (300972.SZ) plans to reduce their shareholding by not more than 0.9594%.
Minami Acoustics (301383.SZ) plans to establish a wholly-owned subsidiary in Ganzhou City.
AOM INT'L (00381) proposes to issue approximately 157.8 million subscription shares at a discount of approximately 11.15%.
Shareholder Zhangzhou Jin Wanchen of Fujian Wanchen Biotechnology Group (300972.SZ) plans to reduce their shareholding by not more than 0.9594%.
RECOMMEND
Anti-Overcompetition Drive Takes Hold Across Multiple Chinese Industries
04/07/2025
Bank of England Governor: Rise of Stablecoins May Undermine Confidence in National Currencies
04/07/2025
What the Passage of the “Big and Beautiful Act” Means for Americans: Gains and Losses Across Demographics
04/07/2025
